# Integrin-Linked Kinase (ILK) Promotes Mitochondrial Dysfunction by Decreasing CPT1A Expression in a Folic Acid-Based Model of Kidney Disease

**Authors:** Mariano de la Serna-Soto, Laura Calleros, María Martos-Elvira, Ariadna Moreno-Piedra, Sergio García-Villoria, Mercedes Griera, Elena Alcalde-Estévez, Ana Asenjo-Bueno, Diego Rodríguez-Puyol, Sergio de Frutos, María Piedad Ruiz-Torres

PMC · DOI: 10.3390/ijms26051861 · 2025-02-21

## TL;DR

This study shows that ILK contributes to kidney damage by reducing mitochondrial function, suggesting it could be a target for treatment.

## Contribution

The study identifies a novel signaling axis involving ILK, GSK3β, and C/EBPβ that regulates CPT1A in mitochondrial dysfunction during kidney disease.

## Key findings

- ILK depletion reversed folic acid-induced renal damage and mitochondrial dysfunction.
- The ILK-GSK3β-C/EBPβ axis regulates CPT1A, a key marker of mitochondrial homeostasis.
- Reduced GSK3β activity and increased fibrosis were observed in FA-induced kidney disease.

## Abstract

Integrin-linked kinase (ILK) is a key scaffolding protein between extracellular matrix protein and the cytoskeleton and has been implicated previously in the pathogenesis of renal damage. However, its involvement in renal mitochondrial dysfunction remains to be elucidated. We studied the role of ILK and its downstream regulations in renal damage and mitochondria function both in vivo and vitro, using a folic acid (FA)-induced kidney disease model. Wild type (WT) and ILK conditional-knockdown (cKD-ILK) mice were injected with a single intraperitoneal dose of FA and studied after 15 days of chronic renal damage progression. Human Kidney tubular epithelial cells (HK2) were transfected with specific siRNAs targeting ILK, glycogen synthase kinase 3-β (GSK3β), or CCAAT/enhancer binding protein-β (C/EBPβ). The expressions and activities of renal ILK, GSK3β, C/EBPβ, mitochondrial oxidative phosphorylation enzymes, and mitochondrial membrane potential were assessed. Additionally, the expression of markers for fibrosis fibronectin (FN) and collagen 1 (COL1A1), for autophagy p62 and cytosolic light chain 3 (LC3B) isoforms II and I, and mitochondrial homeostasis marker carnitine palmitoyl-transferase 1A (CPT1A) were evaluated using immunoblotting, RT-qPCR, immunofluorescence, or colorimetric assays. FA upregulated ILK expression, leading to the decrease of GSK3β activity, increased tubular fibrosis, and produced mitochondrial dysfunction, both in vivo and vitro. These alterations were fully or partially reversed upon ILK depletion, mitigating FA-induced renal damage. The signaling axis composed by ILK, GSK3β, and C/EBPβ regulated CPT1A transcription as the limiting factor in the FA-based impaired mitochondrial activity. We highlight ILK as a potential therapeutical target for preserving mitochondrial function in kidney injury.

## Linked entities

- **Genes:** ILK (integrin linked kinase) [NCBI Gene 3611], GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], CEBPB (CCAAT enhancer binding protein beta) [NCBI Gene 1051], CPT1A (carnitine palmitoyltransferase 1A) [NCBI Gene 1374], FN1 (fibronectin 1) [NCBI Gene 2335], COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277], GTF2H1 (general transcription factor IIH subunit 1) [NCBI Gene 2965], MAP1LC3B (microtubule associated protein 1 light chain 3 beta) [NCBI Gene 81631]
- **Proteins:** ILK (integrin linked kinase), GSK3B (glycogen synthase kinase 3 beta), CEBPB (CCAAT enhancer binding protein beta), CPT1A (carnitine palmitoyltransferase 1A), fn1.S (fibronectin 1 S homeolog), GTF2H1 (general transcription factor IIH subunit 1), MAP1LC3B (microtubule associated protein 1 light chain 3 beta)
- **Chemicals:** folic acid (PubChem CID 135398658)
- **Diseases:** kidney disease (MONDO:0001343)
- **Species:** Mus musculus (taxon 10090), Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, CPT1A (carnitine palmitoyltransferase 1A) [NCBI Gene 1374] {aka CPT I, CPT1, CPT1-L, CPTI-L, L-CPT1}, MAP1LC3B (microtubule associated protein 1 light chain 3 beta) [NCBI Gene 81631] {aka ATG8F, LC3B, MAP1A/1BLC3, MAP1LC3B-a}, NUP62 (nucleoporin 62) [NCBI Gene 23636] {aka IBSN, SNDI, p62}, ILK (integrin linked kinase) [NCBI Gene 3611] {aka HEL-S-28, ILK-1, ILK-2, P59, p59ILK}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], CEBPB (CCAAT enhancer binding protein beta) [NCBI Gene 1051] {aka C/EBP-beta, IL6DBP, NF-IL6, TCF5}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}
- **Diseases:** Kidney Disease (MESH:D007674), chronic renal damage (MESH:D051436), Mitochondrial Dysfunction (MESH:D028361), fibrosis (MESH:D005355)
- **Chemicals:** FA (MESH:D005492)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11899702/full.md

---
Source: https://tomesphere.com/paper/PMC11899702